Alzamend Neuro (ALZN) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing patented therapeutics for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD through two lead candidates: AL001 and ALZN002.

• AL001 is a novel lithium-based formulation designed to improve safety and efficacy over existing lithium treatments, targeting neuropsychiatric and neurodegenerative disorders.

• ALZN002 is an immunotherapy vaccine leveraging autologous dendritic cells to target amyloid-beta proteins in Alzheimer's patients.

• Pipeline strategy includes advancing clinical trials, expanding indications, and optimizing value in major markets.

Financial performance and metrics

• Has experienced significant losses since inception and anticipates continued losses for the foreseeable future.

• Requires substantial additional funding to continue operations and clinical development.

• Financial statements for 2023 and 2024 include going concern opinions from independent auditors.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder, except for potential proceeds from warrant exercises.

• Any proceeds from warrant exercises will be used for general working capital purposes.

• Net proceeds from the sale of preferred shares are expected to be used for working capital and general corporate purposes.